| Literature DB >> 34695199 |
Yasunori Kogure1, Takuro Kameda2, Junji Koya1, Makoto Yoshimitsu3, Kisato Nosaka4, Jun-Ichirou Yasunaga4, Yoshitaka Imaizumi5, Mizuki Watanabe6, Yuki Saito1,7, Yuta Ito1,8, Marni B McClure1, Mariko Tabata1,9, Sumito Shingaki1, Kota Yoshifuji1,10, Kenichi Chiba11, Ai Okada11, Nobuyuki Kakiuchi12, Yasuhito Nannya12, Ayako Kamiunten2, Yuki Tahira2, Keiichi Akizuki2, Masaaki Sekine2, Kotaro Shide2, Tomonori Hidaka2, Yoko Kubuki2, Akira Kitanaka13, Michihiro Hidaka14, Nobuaki Nakano15, Atae Utsunomiya15, R Alejandro Sica16, Ana Acuna-Villaorduna16, Murali Janakiram16, Urvi Shah16, Juan Carlos Ramos17, Tatsuhiro Shibata18,19, Kengo Takeuchi20,21,22, Akifumi Takaori-Kondo6, Yasushi Miyazaki5, Masao Matsuoka4, Kenji Ishitsuka3, Yuichi Shiraishi11, Satoru Miyano23, Seishi Ogawa12, B Hilda Ye24, Kazuya Shimoda2, Keisuke Kataoka1,25.
Abstract
Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform-specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3'-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell-like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.Entities:
Mesh:
Substances:
Year: 2022 PMID: 34695199 PMCID: PMC8854674 DOI: 10.1182/blood.2021013568
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 25.476